Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 40: 130-137, 1994;
This Article
Right arrow Full Text (PDF)
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fossati, P.
Right arrow Articles by Prencipe, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fossati, P.
Right arrow Articles by Prencipe, L.

Clinical Chemistry, Vol 40, 130-137, Copyright © 1994 by American Association for Clinical Chemistry

A step forward in enzymatic measurement of creatinine [published erratum appears in Clin Chem 1995 May;41(5):770]

P Fossati, M Ponti, G Passoni, G Tarenghi, GV Melzi d'Eril and L Prencipe
Research and Development Laboratory, Bayer Diagnostici SpA, Milan, Italy.

We describe an improved enzymatic ultraviolet absorbance method for assaying creatinine in serum, plasma, and urine. Creatinine is hydrolyzed by creatinine iminohydrolase (EC 3.5.4.21) to ammonia and N- methylhydantoin. The ammonia produced combines with 2-oxoglutarate and NADPH in the presence of glutamate dehydrogenase to yield glutamate and NADP+. The consumption of NADPH, measured by a two-point fixed-time assay, is proportional to the amount of creatinine in the sample. The assay is carried out in two steps: The first step eliminates background absorbance in hyperlipemic samples and endogenous ammonia through a "clearing system" and an isocitrate dehydrogenase-based "ammonia scavenger system"; the second step starts creatinine measurement. The method affords a simple, rapid, and sensitive assay with good precision and extended linearity; it employs working solutions stable at least 4 months. Test results compare closely with those of the isotope dilution- mass spectrometry Definitive Method, the HPLC procedure, and the fuller's earth method. The proposed method is not subject to interference from several metabolites or from the 72 drugs tested. Because it is easily automated, the method is suitable for routine work in clinical laboratories.


The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J EndocrinolHome page
A. M McKillop, N. A Duffy, J. R Lindsay, B. D Green, S Patterson, F. P M O'Harte, P. M Bell, and P. R Flatt
Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation
Eur. J. Endocrinol., December 1, 2009; 161(6): 877 - 885.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G.D. Tan, A.V. Lewis, T.J. James, P. Altmann, R.P. Taylor, and J.C. Levy
Clinical Usefulness of Cystatin C for the Estimation of Glomerular Filtration Rate in Type 1 Diabetes: Reproducibility and accuracy compared with standard measures and iohexol clearance
Diabetes Care, November 1, 2002; 25(11): 2004 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. Wyss and R. Kaddurah-Daouk
Creatine and Creatinine Metabolism
Physiol Rev, July 1, 2000; 80(3): 1107 - 1213.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American Association for Clinical Chemistry.